Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF6467 in Paediatric Subjects With Optic Pathway Glioma (OPG)
NCT05733572Phase 2Active, not recruiting
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in optic pathway glioma (OPG) comparing CHF6467 with Placebo (2 arms). Primary endpoint: Visual Field at 6 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
CHF6467
03
Conditions
optic pathway glioma (OPG)
Beyond the preview
Go deeper on NCT05733572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733572.